Metrizamide cisternography and computed tomography for the investigation of pituitary lesions

Sheldon, P.W.E.; Molyneux, Andy

doi:10.1007/bf00556023

Cited by 25 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Morbidity is low when a small dose of metrizamide is used? -s, 6,7 We have performed MCTC in 22 patients, predominantly for tumor, empty sella syndrome, and endocrine abnormalities. The results are summarized and selected case reports presented.…”

Section: T He Advantages Of Computerized Tomography (Ct)mentioning

confidence: 99%

High-resolution metrizamide CT cisternography in sellar and suprasellar abnormalities

Ghoshhajra¹

1981

Journal of Neurosurgery

View full text Add to dashboard Cite

Metrizamide computerized tomographic cisternography was performed with a small dose and low concentration of intrathecal metrizamide using a newer generation of computerized tomography scanner for the evaluation of sellar and suprasellar abnormalities. The examination was performed with thin sections in axial, direct coronal, and (when feasible) direct sagittal projections in a high-resolution technique. The relationship of the lesions with carotid arteries, optic chiasms, and hypothalamic structures was accurately defined.

show abstract

Section: T He Advantages Of Computerized Tomography (Ct)mentioning

confidence: 99%

High-resolution metrizamide CT cisternography in sellar and suprasellar abnormalities

Ghoshhajra¹

1981

Journal of Neurosurgery

View full text Add to dashboard Cite

show abstract

Metrizamide Cisternography in the Investigation of the Empty Sella Syndrome

Zull¹,

Falko

1981

Arch Intern Med

View full text Add to dashboard Cite

Asterixis and encephalopathy following metrizamide myelography: Investigations into possible mechanisms and review of the literature

Bertoni

Schwartzman

Horn

et al. 1981

Annals of Neurology

View full text Add to dashboard Cite

Marked asterixis occurred in two patients following metrizamide myelography. One also suffered generalized seizures and the other had severe stuttering speech for seven days. The spectrum of toxic manifestations of metrizamide is reviewed with emphasis on the unusual lethargy and other depressive effects seen with this relatively safe agent. The hypothesis that metrizamide exerts a ouabain-like effect on the cortical surface was tested. Metrizamide in concentrations as high as 20 mM had no inhibitory effect on rat cerebral K+-para-nitrophenylphosphatase, a partial reaction of (Na+K+)-adenosine triphosphatase. Because metrizamide is a 2-deoxyglucose analogue, a competitive inhibition of hexokinase at the first step in glycolysis was also postulated. Metrizamide was found to competitively inhibit commercial (microbial) hexokinase. The Michaelis constant for glucose rises from 0.13 to 0.25 to 0.33 to 0.91 mM in the presence of 0, 0.4, 1.0, and 2.0 mM metrizamide, respectively. Since the concentration of metrizamide over the cerebral cortex after routine myelography may be approximately 50 mM compared with a glucose concentration of only 3.6 mM (65 mg/dl), it is postulated that impaired brain glucose metabolism may be responsible for some of the toxic effects of metrizamide.

show abstract

Metrizamide cisternography and computed tomography for the investigation of pituitary lesions

Cited by 25 publications

References 6 publications

High-resolution metrizamide CT cisternography in sellar and suprasellar abnormalities

High-resolution metrizamide CT cisternography in sellar and suprasellar abnormalities

Metrizamide Cisternography in the Investigation of the Empty Sella Syndrome

Asterixis and encephalopathy following metrizamide myelography: Investigations into possible mechanisms and review of the literature

Contact Info

Product

Resources

About